Skip to main content

Table 1 Clinical characteristics of patients who underwent genome biopsy with TBB

From: Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study

 

Total patients (n = 572)

(%)

TBB patients (n = 236)

(%)

Re-biopsy in TBB patients (n = 24)

(%)

Age-median, [range]

Median

68 [25–93]

 

68 [25–93]

 

67 [25–79]

 

Sex-no. (%)

Male

365

(63.8)

143

(60.6)

10

(41.6)

Female

207

(36.2)

93

(39.4)

14

(58.4)

Histology-no. (%)

Ad including

396

(69.2)

160

(67.8)

14

(58.4)

 Ad + SCLC

2

 

0

 

0

 

 Ad + Sq

2

 

0

 

0

 

Sq

99

(17.3)

50

(21.2)

5

(20.8)

NSCLC

77

(13.5)

26

(11.0)

5

(20.8)

Stage-n. (%)

IVA, B

416

(72.7)

171

(72.5)

21

(87.5)

IIIA,B,C

140

(24.5)

55

(23.3)

3

(12.5)

IIA, B

16

(2.8)

10

(4.2)

0

 

Tumor location.1

Central

  

69

(29.2)

14

(58.4)

Peripheral

  

167

(70.8)

10

(41.6)

Tumor location.2

Right

      

 Upper and Middle

  

82

(34.7)

10

(41.6)

 Lower

  

42

(17.8)

6

(25.0)

Left

      

 Upper

  

67

(28.4)

4

(16.7)

 Lower

  

45

(19.1)

4

(16.7)

Maximum diameter of tumor.(mm)

Median [range]

  

39.3 [14.7–102.3]

 

49.5 [15.6–82.0]

 

ROSE

Positive

    

21

(87.5)

  1. TBB transbronchial biopsy, Ad adenocarcinoma, SCLC small cell lung carcinoma, Sq squamous cell carcinoma, ROSE rapid-onsite evaluation